2019
The changing therapeutic landscape of head and neck cancer
Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nature Reviews Clinical Oncology 2019, 16: 669-683. PMID: 31189965, DOI: 10.1038/s41571-019-0227-z.Peer-Reviewed Original ResearchConceptsNeck cancerTherapeutic landscapeNeck squamous cell carcinomaFirst immunotherapeutic agentHuman papillomavirus infectionNon-surgical therapyUpper aerodigestive tractSquamous cell carcinomaDifferent treatment modalitiesPapillomavirus infectionAerodigestive tractImmunotherapeutic agentsCell carcinomaTreatment modalitiesClinical trialsOral cavitySalivary glandsWidespread testingHNSCCDevelopment of strategiesCancerCurrent eraHeadOropharynxPatients
2016
Treatment de-intensification strategies for head and neck cancer
Kelly JR, Husain ZA, Burtness B. Treatment de-intensification strategies for head and neck cancer. European Journal Of Cancer 2016, 68: 125-133. PMID: 27755996, PMCID: PMC5734050, DOI: 10.1016/j.ejca.2016.09.006.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellChemoradiotherapyCombined Modality TherapyHead and Neck NeoplasmsHumansMinimally Invasive Surgical ProceduresOropharyngeal NeoplasmsOtorhinolaryngologic Surgical ProceduresPapillomavirus InfectionsRadiotherapy DosageRadiotherapy, AdjuvantSquamous Cell Carcinoma of Head and NeckConceptsHigh-risk human papillomavirus infectionHuman papillomavirus infectionLong-term morbiditySquamous cell cancerSquamous cell carcinomaDe-intensification strategiesIntensive treatment regimensAltered fractionation schemesDefinitive chemoradiationAdjuvant radiationPapillomavirus infectionCell cancerImpairs qualityTreatment regimensCell carcinomaNeck cancerRecent trialsSimilar efficacySuch cancersInvasive surgeryTreatment intensityCancerRadiation dosePreliminary dataSurgery
2012
Management of Human Papillomavirus–Positive and Human Papillomavirus–Negative Head and Neck Cancer
Mehra R, Ang KK, Burtness B. Management of Human Papillomavirus–Positive and Human Papillomavirus–Negative Head and Neck Cancer. Seminars In Radiation Oncology 2012, 22: 194-197. PMID: 22687943, DOI: 10.1016/j.semradonc.2012.03.003.Peer-Reviewed Original ResearchConceptsHPV-positive diseaseNeck carcinomaClinical trialsHuman papillomavirus-negative headOncogenic human papillomavirus (HPV) infectionPack-year smoking historyCurative treatment regimensHPV-negative diseaseHuman Papillomavirus–PositiveHuman papillomavirus infectionSquamous cell headProspective clinical trialsTraditional risk factorsSquamous cell carcinomaHPV-negative headCurrent clinical trialsCombination of radiationIntermediate riskPapillomavirus infectionSmoking historySystemic therapyTreatment regimensCell carcinomaTransoral surgeryNeck cancerECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP).
Marur S, Lee J, Cmelak A, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). Journal Of Clinical Oncology 2012, 30: 5566-5566. DOI: 10.1200/jco.2012.30.15_suppl.5566.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaInduction chemotherapySquamous cell carcinomaQuality of lifeCell carcinomaDay 1Primary siteMedian age 57 yearsResectable squamous cell carcinomaPhase II clinical trialCetuximab loading doseCisplatin 75mg/Pack-years smokingStandard-dose RTTumor stage T1Age 57 yearsHuman papillomavirus infectionPhase II trialProgression-free survivalExpression of biomarkersLow-dose radiationClinical CRRT armTarget accrualToxic regimens